Clinical trials: Affective Disorders
Bipolar Disorder, Schizophrenia
Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)
This study will assess asenapine (Sycrest®) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL®CONSTA®) and olanzapine (Zyprexa®).
- Trial name
- NCT01495741
- Volunteers
- 42 people
- Sponsor
- Organon and Co
Treatment Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale…
- Trial name
- RECOVER (NCT03887715)
- Testing
- Vagus Nerve Stimulation (VNS)
- Where
- 101 sites in United States
- Volunteers
- 6,800 people
- Sponsor
- LivaNova
Schizophrenia, Bipolar Disorder
EMR Data to Assess Monitoring of Patients Treated With Quetiapine
A study to evaluate the effectiveness of an update of educational materials with respect to evaluation of monitoring of metabolic parameters
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT01793324
- Volunteers
- 6,153 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
The purpose of this study is to determine the effect of LY2216684 on heart rate and blood pressure in research participants with MDD who are being treated with an SSRI (selective serotonin reuptake inhibitors).
- Trial name
- NCT01263223
- Testing
- LY2216684
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06786624
- Testing
- NBI-1065845
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Depressive Disorder
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
The primary objective is to evaluate the safety and tolerability of abrupt discontinuation of saredutant over 1 week in outpatients with depression who completed 8 weeks of treatment with saredutant 100 mg once daily.
- Trial name
- NCT00429260
- Testing
- Saredutant
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Sanofi
Major Depressive Disorder
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect…
- Trial name
- NCT02279953
- Testing
- Vortioxetine 10-20 mg, SSRI
- Where
- 17 sites in Estonia, Finland and 3 more
- Volunteers
- 151 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials
A study in patients with depression
- Trial name
- NCT00191594
- Testing
- Duloxetine Hydrochloride
- Where
- 6 sites in Spain
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company
Postpartum Depression, Postnatal Depression
Phase 2 Clinical Trial of GH001 in Postpartum Depression
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 female participants with clinically diagnosed postpartum depression (PPD) will be included in this study.
- Trial name
- NCT05804708
- Testing
- GH001
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 10 people
- Sponsor
- GH Research Ireland Limited
Major Depressive Disorder
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01288079
- Testing
- TC-5214, Duloxetine
- Where
- 63 sites in United States, Estonia and 3 more
- Volunteers
- 145 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD
In this randomized clinical trial, subjects will be assigned to either an assay-guided treatment condition (AGT) or a treatment-as-usual condition (TAU).
- Trial name
- NCT02634177
- Testing
- Assay-guided treatment (AGT), Treatment-as-usual (TAU)
- Where
- 23 sites in United States
- Volunteers
- 305 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Depressive Symptoms
AI Mental Health Tool vs. Psychoeducation Control
The goal of this clinical trial is to learn if Ash, an AI chat tool for mental health, works better than static psychoedcuation in reducing mental health symptoms.
- Trial name
- NCT07841483
- Testing
- Ash, Brief Therapist-Delivered Telehealth
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Slingshot AI
Depressive Disorder, Major, Anxiety Disorders
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and…
- Trial name
- BASIS (NCT04770454)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Major Depressive Disorder
GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects
To evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of GW117 ODT in healthy volunteers
- Trial name
- NCT06964711
- Testing
- GW117 ODT
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
- Trial name
- NCT01573598
- Testing
- Vilazodone
- Where
- 75 sites in United States, Bulgaria and 6 more
- Volunteers
- 1,219 people
- Sponsor
- Forest Laboratories
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Postpartum Depression
A Phase II Study of HS-10353 in Participants With Postpartum Depression
The primary purpose of this study is to determine if treatment with HS-10353 reduces depressive symptoms in participants with postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item…
- Trial name
- NCT05937867
- Testing
- HS-10353 Capsules 30 mg, Oral, QN for 14 days, HS-10353 Capsules 50 mg, Oral, QN for 14 days
- Volunteers
- 96 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Depression, Depressive Disorder
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00366652
- Testing
- desvenlafaxine SR, desipramine, duloxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer